Reimagining Medicine

Company overview Innovation: Pipeline overview Cardiovascular Financial review Immunology ianalumab - BAFF-R inhibitor 2023 priorities Innovation: Clinical trials Neuroscience Oncology ianalumab - BAFF-R inhibitor Appendix Abbreviations Other NCT03217422 AMBER (CVAY736B2201) Indication Autoimmune hepatitis Phase Phase 2 Patients 65 Primary Outcome Alanine aminotransferase (ALT) normalization Measures Arms VAY736 Intervention Target Placebo control with conversion to active VAY736 Autoimmune hepatitis patients with incomplete response or intolerant to standard treatment of care Patients Readout 2024 Milestone(s) Publication TBD NCT05126277 SIRIUS-LN (CVAY736K12301) Lupus Nephritis Phase 3 Indication Phase Patients 420 Primary Outcome Measures Arms Intervention Target Patients Readout Milestone(s) Frequency and percentage of participants achieving complete renal response (CRR) [ Time Frame: week 72] Arm 1: Experimental -ianalumab s.c. q4w in addition to standard of care (SoC) Arm 2: Experimental - ianalumab s.c. q12w in addition to SoC Arm 3: Placebo comparator - Placebo s.c. q4w in addition to SoC Patients with active Lupus Nephritis Primary 2027 Publication TBD 70 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine

View entire presentation